The startup develops non-invasive diagnostic tests that utilize proprietary epigenetic and molecular technologies to detect specific methylation biomarkers for various cancers. These tests enable healthcare institutions to enhance early cancer detection and improve patient outcomes through precise biomarker identification.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for bladder cancer detection often involve invasive procedures like cystoscopy, leading to patient discomfort and increased healthcare costs. Traditional diagnostic approaches may also lack the sensitivity needed for early detection, potentially delaying treatment and impacting patient outcomes.
Solution
Promis DX offers EarlyTect® BCD, a non-invasive urine test for the early detection of bladder cancer. The test utilizes a patented LTE-qMSP technology to analyze methylated DNA, which serves as a biomarker for cancer. By combining linear target enrichment and quantitative methylation-specific PCR in a single closed tube, EarlyTect® BCD minimizes contamination risks and enhances accuracy. This method allows for the detection of bladder cancer across all stages, including high-grade and advanced stages, with high sensitivity and specificity. A negative test result also reliably indicates the absence of bladder cancer, potentially reducing the need for invasive procedures.
Target Audience
The primary target audience includes healthcare providers, urologists, and oncologists seeking a non-invasive and accurate method for early bladder cancer detection in patients presenting with hematuria or at risk for bladder cancer recurrence.
Features
- Non-invasive urine-based test for bladder cancer detection
- Employs patented LTE-qMSP technology for methylated DNA analysis
- Combines linear target enrichment and quantitative methylation-specific PCR in a single closed tube
- Demonstrated 81.0% sensitivity and 91.5% specificity in detecting bladder cancer across all stages
- 100% sensitivity rate for high-grade and advanced stages of bladder cancer
- High negative predictive value of 97.7%, reducing the need for cystoscopies
- Streamlined workflow minimizes contamination risks and enhances test accuracy